Novel Plasma Fractionation Process to Produce Intravenous Immunoglobulin (IVIG)

Wednesday, October 19, 2022

9:30 AM – 10:30 AM ET

Location:360 Stage #2, Exhibit Hall A&B

Presented By

Manufacturing and Analytical Characterization

Tech Spotlight Speaker(s)

Matthew Whelihan, PhD (he/him/his)

Associate Principal Scientist
Prolytix
Essex Juction, Vermont

Handouts

Description: IVIG fractionated from human plasma is used to treat various autoimmune, infectious, and idiopathic diseases. For over 70 years, IVIG has been produced with the Cohn process which requires large volumes of ethanol. Here we describe a fundamentally different process to produce IVIG. This process requires less time (reducing the cost), produces higher yield (reducing the demand for blood donations), and has greater purity (reducing the risk of adverse events).

Learning Objectives:

Define the risks associated with long-term administration of IVIG
Define the opportunities to improve the current process for plasma fractionation
Understand how the new process reduces the impact on the environment, reduces the demand for healthy blood donations, and reduces the risk to patient safety